Pharmacokinetics of high-dose meropenem in adult cystic fibrosis patients.
Because patients with cystic fibrosis (CF) have pulmonary exacerbations secondary to multi-antibiotic-resistant Gram-negative bacilli, antibiotics, like meropenem, are often utilized. We studied the pharmacokinetics of meropenem (2 g i.v. administered every 8 h in clinically stable CF patients to determine if the recommended maximum doses could sustain adequate concentrations during the dosing interval. These pharmacokinetic data were similar to those obtained in non-CF populations. Using this regimen, concentrations of meropenem exceed the susceptibility breakpoint (4 microg/ml) for 50% of the dosing interval, and therefore provide optimization of the pharmacodynamic profile of the compound.
Bui
K Q
KQ
Bristol-Myers Squibb Company, Plainsboro, NJ, USA.
Ambrose
P G
PG
Nicolau
D P
DP
Lapin
C D
CD
Nightingale
C H
CH
Quintiliani
R
R
D000293:Adolescent; D000328:Adult; D003550:Cystic Fibrosis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D000077731:Meropenem; D013845:Thienamycins / Q000493:pharmacokinetics*
D013845:Thienamycins; D000077731:Meropenem